Lena Chaihorsky discusses how to align incentives and develop tests that payers want to pay for. Check out the Video HERE
Our VP of Payer Innovation Lena Chairhorsky spoke on a panel discussing reimbursement models for gene and cell therapies, and how diagnostics could be instrumental in proving their value and creating a sustainable model that allows developers and patients to be successful. Full agenda HERE
Explore where and why the status quo reimbursement model is not working for the diagnostics industry in a session with Lena Chaihorsky at the annual Q1 Diagnostic Coverage & Reimbursement Conference. Check out the annual Q1 conference series HERE.
Lena Chaihorsky joins a panel discussion led by the Get the Medications Right (GTMRx) Institute to raise awareness among employers about the low efficacy and high cost of specialty drugs. Check out a recap of the conversation HERE.
Lena Chaihorsky joins a virtual panel discussion focused on understanding how to translate the national conversation around diagnostic importance into long term change for the diagnostic industry. See the agenda HERE.
Join Lena Chaihorsky for a discussion around prioritizing reimbursement as an early–stage biotech start-up. Learn about the historic mistakes made in the industry and learn how to set yourself up for success directly from a payer. Register HERE.
Lena Chaihorsky, Alva10’s VP of Payer Innovation reviews the hard truths about specialty drug efficacy rates and the ‘trial and error’ patterns of treating patients in the absence of diagnostics today, while offering solutions employers can implement today to decrease costs and improve outcomes. See the agenda HERE.
Hannah Mamuszka and Blake Long, MD, of Alva10 join host Joe Selvaggi to discuss the role that Pharmacy Benefit Managers play in the high cost of prescription drugs in the US. Listen HERE.
Alva10 CEO Hannah Mamuszka and Erika Spaeth, PhD Director, Clinical Affairs, Phenogen Sciences discuss how a polygenic risk score for breast cancer can better assess risk for developing breast cancer than relying on BRCA status or family history alone. 85% of women who get breast cancer do not have a BRCA gene mutation and do not have family history of breast cancer. Watch HERE.
Catch VP Lena Chaihorsky in conversation with Welldyne PBM’s Chief Medical Officer Nick Page about the innovative ways PBMs can engage with the diagnostic industry to support their own value propositions, and in so doing create an alternative market pathway for this critical category of healthcare tools. Watch HERE.
Lena Chaihorsky leads a panel discussion on the early adopters of diagnostics and the pilot programs that can get valuable diagnostics through the toughest period of early commercialization. Join us! Agenda here.
The pandemic has made everyone realize the importance of diagnostics in healthcare, but 8 months into the pandemic, we still lack the diagnostics we need to best manage Covid-19. How can we incentivize the development of the diagnostics we need to find disease, determine risk, and assess immunity? What are the regulatory barriers, and how can they be overcome? Who pays for these tests? What can we learn from Covid-19 for the next pandemic?
Diagnostic tests can be well validated, accepted in guidelines, and even reimbursed, yet they still don’t impact patient care. Why? Improper use, lack of physician understanding & support, lack of inclusion in coverage policies, inability to track all contribute to losing the potential impact of critical diagnostic tools. Software that highlights & streamlines decision making and provides information at the point of care allows for more efficient precision delivery of these tools.
Precision Medicine usually connotes use of diagnostics and other tools to optimize care in oncology, but really we should be considering development and use of these tools in every disease area. We will discuss the challenges around development and commercialization of Precision Medicine diagnostics for use in stroke and autoimmune diseases.
Hannah Mamuszka & Satabhisa Mukhopadhyay PhD, MS, Chief Scientific Officer & Founder, 4D Path discuss the potential for digital pathology to supplant IHC, PCR, FISH, & NGS in oncology, dramatically reducing cost & increasing patient access.
October 2019— Hannah Mamuszka, CEO, Alva10 on Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders
Registration Required for Access.